Correction to Lancet Oncol 2017; 18: 812

Published Erratum

. 2017 Jun;18(6):e301.

doi: 10.1016/S1470-2045(17)30371-6.

No authors listed

Published Erratum

No authors listed. Lancet Oncol. 2017 Jun.

. 2017 Jun;18(6):e301.

doi: 10.1016/S1470-2045(17)30371-6.

No abstract available

Erratum for

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Lancet Oncol. 2017. PMID: 28499583 Clinical Trial.